“Early” Class III Drugs for the Treatment of Atrial Fibrillation
Open Access
- 28 September 2004
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 110 (13), 1717-1724
- https://doi.org/10.1161/01.cir.0000143050.22291.2e
Abstract
Background— Currently available antiarrhythmic drugs are only moderately effective against atrial fibrillation (AF) and may cause ventricular proarrhythmia. AVE0118 is a blocker of atrium-specific early K+ currents (IKur/Ito).Keywords
This publication has 12 references indexed in Scilit:
- Atrial effects of the novel K+-channel-blocker AVE0118 in anesthetized pigsCardiovascular Research, 2003
- Electrophysiologic actions of dl-sotalolin patients with persistent atrial fibrillationJournal of the American College of Cardiology, 2002
- Isolated Noncompaction of the MyocardiumCirculation, 2002
- Cellular electrophysiology of atrial fibrillationCardiovascular Research, 2002
- Effects of a Novel Class III Antiarrhythmic Agent, NIP-142, on Canine Atrial Fibrillation and FlutterCirculation Journal, 2002
- Dofetilide in Patients with Congestive Heart Failure and Left Ventricular DysfunctionNew England Journal of Medicine, 1999
- Electrical Remodeling of the Human Atrium: Similar Effects in Patients With Chronic Atrial Fibrillation and Atrial FlutterJournal of the American College of Cardiology, 1997
- Intravenous Dofetilide, a Class III Antiarrhythmic Agent, for the Termination of Sustained Atrial Fibrillation or FlutterJournal of the American College of Cardiology, 1997
- Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarctionThe Lancet, 1996
- Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: A dose-response studyJournal of the American College of Cardiology, 1996